在痛风患者中使用febuxostat与allopurinol:现实世界的研究
Josephin Voskamp1, Anne-Kathrin Tausche1
1Internal Medicine/Rheumatology, Dresden University Hospital, Dresden, DEU.
这项研究观察了用阿洛普林诺或费布克苏斯塔特治疗的痛风患者,在费布克苏斯塔特组发现更多的心血管事件,尽管风险因素较高. 需要仔细考虑治疗方案.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 流行病学 流行病学
背景情况:
- 痛风是一种常见的疾病,需要尿酸降低治疗.
- 心血管事件是痛风患者的一个重大问题.
- 了解痛风药物的比较安全性至关重要.
研究的目的:
- 为了对一群痛风患者进行流行病学观察.
- 用于表征心血管事件和痛风患者的死亡率,这些患者接受了阿洛普里诺,费布克苏斯塔特或没有尿酸降低治疗.
- 分析并发症和共用药对结果的影响.
主要方法:
- 这是一项对208名痛风患者的观察研究.
- 随访时间平均为4.8年.
- 基于初级尿酸降低药物使用的关联研究 (≥60%的随访).
主要成果:
- 18.1%的费布可斯塔特使用者和7.5%的阿洛普林醇使用者经历了心血管事件.
- 死亡率为febuxostat用户的6.9%,而allopurinol用户的6%.
- 在febuxostat组中,风险因素的患病率较高.
结论:
- 费布可斯塔特组有更多的心血管事件,与较高的风险因素患病率有关.
- 解释这些发现需要仔细考虑,因为常见的临床情景.
- 在选择痛风治疗时,个性化患者评估是必不可少的.
更多相关视频
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
11:47Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Obese Patients
Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
